Andere Sprachen United Therapeutics Corporation

Aktien

923818

US91307C1027

UTHR

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 06.03.2026			% 5 Tage	Veränd. 1. Jan.
478,16 ^USD	-1,42 %		-5,11 %	-1,87 %

05.03.	United Therapeutics-Insider verkauft Aktien im Wert von 4.744.467 US-Dollar laut aktueller SEC-Meldung	MT
05.03.	United Therapeutics bleibt laut UBS dank mehrerer kurzfristiger Katalysatoren Top-Empfehlung	MT

Andere Sprachen

05.03.	United Therapeutics Insider Sold Shares Worth $4,744,467, According to a Recent SEC Filing
05.03.	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says
03.03.	United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
02.03.	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
02.03.	United Therapeutics Corporation announces ralinepag achieved 55% reduction in risk of clinical worsening in pivotal pulmonary arterial hypertension study, delivering exceptional, highly statistically significant efficacy
02.03.	United Therapeutics Says Ralinepag Cut Risk of Clinical Worsening by 55% in Phase 3 Study
02.03.	United Therapeutics' drug slows progression of rare lung condition in late-stage study
02.03.	United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
02.03.	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
26.02.	United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says
25.02.	United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
25.02.	Stocks Rise Pre-Bell Ahead of Nvidia's Latest Quarterly Results
25.02.	United Therapeutics Q4 Earnings, Revenue Increase
25.02.	United Therapeutics: Q4 Earnings Snapshot
25.02.	United Therapeutics : Fourth Quarter 2025 Financial Results Presentation
25.02.	United Therapeutics : Fourth Quarter 2025 Factsheet
25.02.	Earnings Flash (UTHR) United Therapeutics Corporation Reports Q4 Revenue $790.2M, vs. FactSet Est of $811.4M
25.02.	Earnings Flash (UTHR) United Therapeutics Posts Q4 EPS $7.70, vs. FactSet Est of $6.67
25.02.	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
23.02.	United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
11.02.	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
26.01.	United Therapeutics Corporation Announces Positive Results from Phase 1 Study of MiroliverELAP® in Patients with Acute Liver Failure
26.01.	United Therapeutics Says Its Experimental Liver Assist Device Met Primary Goal in Phase 1 Study
26.01.	United Therapeutics announces positive results from phase 1 study of Miroliverelap in patients with acute liver failure
26.01.	United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure